论文部分内容阅读
目的:观察重组人生长激素(rhGH)治疗小于胎龄儿(SGA)持续矮小的疗效和安全性。方法:17例出生时为SGA且目前诊为矮小的患儿,随机分为2组,每晚睡前1 h皮下注射rhGH,低剂量组8例,0.1 U/(kg.d),高剂量组9例,0.2 U/(kg.d),观察12个月。结果:17例患儿身高由治疗前(96.34±8.94)cm增至治疗后的(107.32±9.58)cm,骨龄(BA)由治疗前的(2.39±1.28)岁增至(3.64±1.76)岁,年龄对应身高标准差积分(HtSDSCA)治疗前-3.04±0.79增至治疗后-1.89±0.79,生长速率(GV)由治疗前(4.59±0.87)cm/年增至治疗后(11.24±1.91)cm/年,预测身高(PAH)由治疗前(147.24±5.70)cm,增至治疗后(153.53±6.17)cm。两组患儿治疗前后的变化差异均有统计学意义(P<0.05)。不同剂量组均有促生长作用,无统计学差异。结论:rhGH对SGA持续矮小患儿有促生长作用,使其达到追赶生长,且不良反应少。
Objective: To observe the efficacy and safety of recombinant human growth hormone (rhGH) in treating short-term small-gestated children (SGA). Methods: 17 cases of SGA at birth and currently diagnosed as short stature were randomly divided into 2 groups. Each group received rhGH subcutaneously 1 h before bedtime each night. Eight patients in low dose group (0.1 U / (kg.d)), high dose Group 9 cases, 0.2 U / (kg.d), observed for 12 months. Results: The height of 17 patients increased from (96.34 ± 8.94) cm to (107.32 ± 9.58) cm after treatment, while the BA increased from 2.39 ± 1.28 to 3.64 ± 1.76 before treatment (HtSDSCA) increased from -3.04 ± 0.79 to -1.89 ± 0.79 before treatment, and the growth rate increased from 4.59 ± 0.87 cm / year to 11.24 ± 1.91 before treatment (HtSDSCA) cm / year. The predicted height (PAH) increased from 147.24 ± 5.70 cm before treatment to 153.53 ± 6.17 cm after treatment. The difference between the two groups before and after treatment were statistically significant (P <0.05). Different dose groups have growth-promoting effect, no statistical difference. CONCLUSION: rhGH can promote the growth of children with SAG in short duration and catch up with growth with little adverse reactions.